Literature DB >> 21078794

68Ga-DOTANOC PET/CT allows somatostatin receptor imaging in idiopathic pulmonary fibrosis: preliminary results.

Valentina Ambrosini1, Maurizio Zompatori, Fiorella De Luca, D'Errico Antonia, Vincenzo Allegri, Cristina Nanni, Deborah Malvi, Eva Tonveronachi, Luca Fasano, Mario Fabbri, Stefano Fanti.   

Abstract

UNLABELLED: Interstitial lung diseases include different clinical entities with variable prognoses. Idiopathic pulmonary fibrosis (IPF), the most common, presents the most severe outcome (death within 3-5 y), whereas nonspecific interstitial pneumonia (NSIP) shows a more indolent progression. Preclinical evidence of somatostatin receptor (SSTR) expression on fibroblasts in vitro and in lung fibrosis murine models, coupled with the longer survival of mice with fibrotic lungs treated with agents blocking SSTR, supports the hypothesis of imaging fibroblast activity in vivo by visualization of SSTR with (68)Ga-DOTANOC PET/CT. The aim of this study was to evaluate (68)Ga-DOTANOC PET/CT in patients with IPF and NSIP.
METHODS: Seven IPF patients and 7 NSIP patients were included in the study. (68)Ga-DOTANOC PET/CT and high-resolution CT (HRCT) were performed in all cases by following a standard procedure. PET/CT results were compared with disease sites and extent on HRCT.
RESULTS: In IPF, (68)Ga-DOTANOC uptake was peripheral, subpleural, and directly correlated with pathologic areas on HRCT (subpleural/reticular fibrosis, honeycombing). NSIP patients showed fainter tracer uptake, whereas corresponding HRCT showed areas of ground-glass opacity and rare fibrotic changes. Only IPF patients showed a linear correlation between maximal SUV and disease extent quantified both automatically (Q) (IPF: P = 0.002, R = 0.93) and using the visual score (Spearman ρ = 0.46, P = 0.0001). Q directly correlated with percentage carbon monoxide diffusing capacity in IPF (P = 0.03, R = 0.79) and NSIP (P = 0.05, R = 0.94), whereas maximal SUV did not present any correlation with percentage carbon monoxide diffusing capacity.
CONCLUSION: Our preliminary data show that (68)Ga-DOTANOC PET/CT demonstrates SSTR overexpression in IPF patients; this may prove interesting for the evaluation of novel treatments with somatostatin analogs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21078794     DOI: 10.2967/jnumed.110.079962

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  29 in total

Review 1.  Gallium-labelled peptides for imaging of inflammation.

Authors:  Anne Roivainen; Sirpa Jalkanen; Cristina Nanni
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

2.  Optimization of a Collagen-Targeted PET Probe for Molecular Imaging of Pulmonary Fibrosis.

Authors:  Pauline Désogère; Luis F Tapias; Tyson A Rietz; Nicholas Rotile; Francesco Blasi; Helen Day; Justin Elliott; Bryan C Fuchs; Michael Lanuti; Peter Caravan
Journal:  J Nucl Med       Date:  2017-06-13       Impact factor: 10.057

3.  The importance of correction for tissue fraction effects in lung PET: preliminary findings.

Authors:  Tryphon Lambrou; Ashley M Groves; Kjell Erlandsson; Nick Screaton; Raymondo Endozo; Thida Win; Joanna C Porter; Brian F Hutton
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-08-27       Impact factor: 9.236

4.  Type I Collagen-targeted Positron Emission Tomography Imaging in Idiopathic Pulmonary Fibrosis: First-in-Human Studies.

Authors:  Sydney B Montesi; David Izquierdo-Garcia; Pauline Désogère; Eric Abston; Lloyd L Liang; Subba Digumarthy; Ravi Seethamraju; Michael Lanuti; Peter Caravan; Ciprian Catana
Journal:  Am J Respir Crit Care Med       Date:  2019-07-15       Impact factor: 21.405

Review 5.  Imaging Pulmonary Inflammation.

Authors:  Philip M Scherer; Delphine L Chen
Journal:  J Nucl Med       Date:  2016-09-01       Impact factor: 10.057

6.  Type I collagen-targeted PET probe for pulmonary fibrosis detection and staging in preclinical models.

Authors:  Pauline Désogère; Luis F Tapias; Lida P Hariri; Nicholas J Rotile; Tyson A Rietz; Clemens K Probst; Francesco Blasi; Helen Day; Mari Mino-Kenudson; Paul Weinreb; Shelia M Violette; Bryan C Fuchs; Andrew M Tager; Michael Lanuti; Peter Caravan
Journal:  Sci Transl Med       Date:  2017-04-05       Impact factor: 17.956

7.  18F-Fluorodeoxyglucose positron emission tomography pulmonary imaging in idiopathic pulmonary fibrosis is reproducible: implications for future clinical trials.

Authors:  Thida Win; Tryphon Lambrou; Brian F Hutton; Irfan Kayani; Nicholas J Screaton; Joanna C Porter; Toby M Maher; Raymondo Endozo; Robert I Shortman; Pauline Lukey; Ashley M Groves
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11-30       Impact factor: 9.236

Review 8.  Molecular imaging of fibrosis: recent advances and future directions.

Authors:  Sydney B Montesi; Pauline Désogère; Bryan C Fuchs; Peter Caravan
Journal:  J Clin Invest       Date:  2019-01-02       Impact factor: 14.808

9.  Matrix Metalloproteinase-Targeted Imaging of Lung Inflammation and Remodeling.

Authors:  Reza Golestani; Mahmoud Razavian; Yunpeng Ye; Jiasheng Zhang; Jae-Joon Jung; Jakub Toczek; Kiran Gona; Hye-Yeong Kim; Jack A Elias; Chun Geun Lee; Robert J Homer; Mehran M Sadeghi
Journal:  J Nucl Med       Date:  2016-07-28       Impact factor: 10.057

10.  Apoptotic PET Imaging of Rat Pulmonary Fibrosis with Small-Molecule Radiotracer.

Authors:  Ying Xiong; Dahong Nie; Shaoyu Liu; Hui Ma; Shu Su; Aixia Sun; Jing Zhao; Zhanwen Zhang; Xianhong Xiang; Ganghua Tang
Journal:  Mol Imaging Biol       Date:  2019-06       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.